These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27846073)

  • 1. Brief Report: Preventing HIV-1 Infection in Women Using Oral Preexposure Prophylaxis: A Meta-analysis of Current Evidence.
    Hanscom B; Janes HE; Guarino PD; Huang Y; Brown ER; Chen YQ; Hammer SM; Gilbert PB; Donnell DJ
    J Acquir Immune Defic Syndr; 2016 Dec; 73(5):606-608. PubMed ID: 27846073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
    Adams JL; Shelley K; Nicol MR
    Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Curry SJ; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Jun; 321(22):2203-2213. PubMed ID: 31184747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral Pre-Exposure Prophylaxis Does Not Enhance Immune Responses to HIV in Exposed but Uninfected Persons.
    Pattacini L; Murnane PM; Baeten JM; Fluharty TR; Thomas KK; Bukusi E; Katabira E; Mugo N; Donnell D; Lingappa JR; Celum C; Marzinke M; McElrath MJ; Lund JM;
    J Infect Dis; 2015 Jun; 211(12):1943-52. PubMed ID: 25520426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
    Bekker LG; Roux S; Sebastien E; Yola N; Amico KR; Hughes JP; Marzinke MA; Hendrix CW; Anderson PL; Elharrar V; Stirratt M; Rooney JF; Piwowar-Manning E; Eshleman SH; McKinstry L; Li M; Dye BJ; Grant RM;
    Lancet HIV; 2018 Feb; 5(2):e68-e78. PubMed ID: 28986029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in pre-exposure prophylaxis for HIV.
    Desai M; Field N; Grant R; McCormack S
    BMJ; 2017 Dec; 359():j5011. PubMed ID: 29229609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.
    Spinner CD; Boesecke C; Zink A; Jessen H; Stellbrink HJ; Rockstroh JK; Esser S
    Infection; 2016 Apr; 44(2):151-8. PubMed ID: 26471511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-exposure Prophylaxis Use by Breastfeeding HIV-Uninfected Women: A Prospective Short-Term Study of Antiretroviral Excretion in Breast Milk and Infant Absorption.
    Mugwanya KK; Hendrix CW; Mugo NR; Marzinke M; Katabira ET; Ngure K; Semiyaga NB; John-Stewart G; Muwonge TR; Muthuri G; Stergachis A; Celum CL; Baeten JM
    PLoS Med; 2016 Sep; 13(9):e1002132. PubMed ID: 27676257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations.
    Fonner VA; Dalglish SL; Kennedy CE; Baggaley R; O'Reilly KR; Koechlin FM; Rodolph M; Hodges-Mameletzis I; Grant RM
    AIDS; 2016 Jul; 30(12):1973-83. PubMed ID: 27149090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
    Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
    Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation.
    Marcus JL; Hurley LB; Hare CB; Nguyen DP; Phengrasamy T; Silverberg MJ; Stoltey JE; Volk JE
    J Acquir Immune Defic Syndr; 2016 Dec; 73(5):540-546. PubMed ID: 27851714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.
    Thomson KA; Baeten JM; Mugo NR; Bekker LG; Celum CL; Heffron R
    Curr Opin HIV AIDS; 2016 Jan; 11(1):18-26. PubMed ID: 26417954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV preexposure prophylaxis for adolescents and young adults.
    Allen E; Gordon A; Krakower D; Hsu K
    Curr Opin Pediatr; 2017 Aug; 29(4):399-406. PubMed ID: 28598901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.
    Heffron R; Mugo N; Were E; Kiarie J; Bukusi EA; Mujugira A; Frenkel LM; Donnell D; Ronald A; Celum C; Baeten JM;
    AIDS; 2014 Nov; 28(18):2771-6. PubMed ID: 25493602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.